Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Head and Neck Cancer

  Free Subscription


Articles published in J Nucl Med

Retrieve available abstracts of 35 articles:
HTML format



Single Articles


    January 2024
  1. GU B, Yang Z, Du X, Xu X, et al
    Imaging of Tumor Stroma Using (68)Ga-FAPI PET/CT to Improve Diagnostic Accuracy of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative Imaging Trial.
    J Nucl Med. 2024 Jan 25:jnumed.123.266556. doi: 10.2967/jnumed.123.266556.
    PubMed     Abstract available


  2. ZHAO L, Pang Y, Fang J, Chen J, et al
    Design, Preclinical Evaluation, and Clinical Translation of (68)Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma.
    J Nucl Med. 2024 Jan 4:jnumed.123.266183. doi: 10.2967/jnumed.123.266183.
    PubMed     Abstract available


    December 2023
  3. VENTURA D, Dittmann M, Buther F, Schafers M, et al
    Diagnostic Performance of [(18)F]TFB PET/CT Compared with Therapeutic Activity [(131)I]Iodine SPECT/CT and [(18)F]FDG PET/CT in Recurrent Differentiated Thyroid Carcinoma.
    J Nucl Med. 2023 Dec 21:jnumed.123.266513. doi: 10.2967/jnumed.123.266513.
    PubMed     Abstract available


    November 2023
  4. GUNTHER T, Holzleitner N, Viering O, Beck R, et al
    Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [(68)Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer.
    J Nucl Med. 2023 Nov 9:jnumed.123.266537. doi: 10.2967/jnumed.123.266537.
    PubMed     Abstract available


    October 2023
  5. LASCHINSKY C, Theurer S, Herold T, Rawitzer J, et al
    Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma.
    J Nucl Med. 2023 Oct 26:jnumed.123.266044. doi: 10.2967/jnumed.123.266044.
    PubMed     Abstract available


    June 2023
  6. ENKE JS, Bundschuh RA, Wienand G, Reitsam NG, et al
    Somatostatin Receptor Antagonists as a Theranostic Option in Iodine-Refractory Thyroid Carcinoma.
    J Nucl Med. 2023 Jun 15:jnumed.123.265639. doi: 10.2967/jnumed.123.265639.
    PubMed    


    May 2023
  7. MALIHA PG, Mendelsohn AH, Czernin J, Howard T, et al
    Obstructive Sialadenitis from Oral Squamous Cell Carcinoma: [(68)Ga]Ga-FAPI-46 PET-Positive and [(18)F]FDG PET-Negative.
    J Nucl Med. 2023 May 25:265498. doi: 10.2967/jnumed.123.265498.
    PubMed    


  8. GABRIELS RY, van Heijst LE, Hooghiemstra WTR, van der Waaij AM, et al
    Detection of Early Esophageal Neoplastic Barrett Lesions with Quantified Fluorescence Molecular Endoscopy Using Cetuximab-800CW.
    J Nucl Med. 2023;64:803-808.
    PubMed     Abstract available


    April 2023
  9. TAPROGGE J, Abreu C, Yusuf S, Ainsworth G, et al
    The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer.
    J Nucl Med. 2023 Apr 28:jnumed.122.264913. doi: 10.2967/jnumed.122.264913.
    PubMed     Abstract available


    March 2023
  10. CIVAN C, Kasper S, Berliner C, Fragoso-Costa P, et al
    PSMA-Directed Imaging and Therapy of Salivary Gland Tumors: A Single-Center Retrospective Study.
    J Nucl Med. 2023;64:372-378.
    PubMed     Abstract available


    January 2023
  11. VON GUGGENBERG E, Uprimny C, Klingler M, Warwitz B, et al
    Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the (68)Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer.
    J Nucl Med. 2023 Jan 19:jnumed.122.264977. doi: 10.2967/jnumed.122.264977.
    PubMed     Abstract available


    December 2022
  12. HERRMANN K, Giovanella L, Santos A, Gear J, et al
    Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center.
    J Nucl Med. 2022;63:1836-1843.
    PubMed     Abstract available


    November 2022
  13. LUMISH MA, Maron SB, Paroder V, Chou JF, et al
    Noninvasive assessment of human epidermal growth factor receptor 2 (HER2) in esophagogastric cancer using (89)Zr-trastuzumab PET: a pilot study.
    J Nucl Med. 2022 Nov 23:jnumed.122.264470. doi: 10.2967/jnumed.122.264470.
    PubMed     Abstract available


  14. OEVERHAUS M, Koenen J, Bechrakis N, Stohr M, et al
    Radioiodine ablation of thyroid remnants in patients with Graves' orbitopathy.
    J Nucl Med. 2022 Nov 23:jnumed.122.264660. doi: 10.2967/jnumed.122.264660.
    PubMed     Abstract available


  15. ZHOU Q, van den Berg NS, Kang W, Pei J, et al
    Factors for Differential Outcome Across Cancers in Clinical Molecule-Targeted Fluorescence Imaging.
    J Nucl Med. 2022;63:1693-1700.
    PubMed     Abstract available


    October 2022
  16. HU X, Zhou T, Ren J, Duan J, et al
    Response prediction using (18)F-FAPI-04 PET/CT in patients with esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy.
    J Nucl Med. 2022 Oct 13. pii: jnumed.122.264638. doi: 10.2967/jnumed.122.264638.
    PubMed     Abstract available


    September 2022
  17. SUBRAMANIAM RM, DeMora L, Yao M, Yom SS, et al
    (18)F FDG PET/CT Prediction of Treatment Outcomes in HPV-positive, Locally Advanced Oropharyngeal Cancer Receiving De-intensified Therapy: Results from NRG-HN002.
    J Nucl Med. 2022 Sep 2. pii: jnumed.122.264424. doi: 10.2967/jnumed.122.264424.
    PubMed     Abstract available


    August 2022
  18. KRISHNAN G, van den Berg NS, Nishio N, Kapoor S, et al
    Fluorescent Molecular Imaging Can Improve Intraoperative Sentinel Margin Detection in Oral Squamous Cell Carcinoma.
    J Nucl Med. 2022;63:1162-1168.
    PubMed     Abstract available


    June 2022
  19. ZHENG KH, Kroon J, Schoormans J, Gurney-Champion O, et al
    (89)Zr-labeled High-Density Lipoprotein Nanoparticle PET imaging reveals tumor uptake in patients with esophageal cancer.
    J Nucl Med. 2022 Jun 23. pii: jnumed.121.263330. doi: 10.2967/jnumed.121.263330.
    PubMed     Abstract available


  20. AVRAM AM, Giovanella L, Greenspan B, Lawson SA, et al
    SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version.
    J Nucl Med. 2022;63:15N-35N.
    PubMed    


    May 2022
  21. SUBRAMANIAM RM, Duan F, Romanoff J, Yu JQ, et al
    (18)F FDG PET/CT Staging of Head and Neck Cancer: Inter-observer agreement and accuracy - Results from multicenter ACRIN 6685 Clinical Trial.
    J Nucl Med. 2022 May 12. pii: jnumed.122.263902. doi: 10.2967/jnumed.122.263902.
    PubMed     Abstract available


  22. VERHOEFF SR, van de Donk PP, Aarntzen EHJG, Oosting SF, et al
    (89)Zr-DFO-durvalumab PET/CT prior to durvalumab treatment in patients with recurrent or metastatic head and neck cancer.
    J Nucl Med. 2022 May 5. pii: jnumed.121.263470. doi: 10.2967/jnumed.121.263470.
    PubMed     Abstract available


    February 2022
  23. SIGNORE A, Campagna G, Marinaccio J, de Vitis M, et al
    Analysis of short term and stable DNA damage in patients with differentiated thyroid cancer treated with (131)I in hypothyroidism or with rhTSH for remnant ablation.
    J Nucl Med. 2022 Feb 3. pii: jnumed.121.263442. doi: 10.2967/jnumed.121.263442.
    PubMed     Abstract available


    December 2021
  24. CREFF G, Jegoux F, Palard-Novello X, Depeursinge A, et al
    FDG-PET/CT-based prognostic survival model after surgery for head and neck cancer.
    J Nucl Med. 2021 Dec 9. pii: jnumed.121.262891. doi: 10.2967/jnumed.121.262891.
    PubMed     Abstract available


  25. RISOER LM, Clausen MM, Ujmajuridze Z, Farhadi M, et al
    Prognostic value of Urokinase-type Plasminogen Activator Receptor (uPAR)-PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with (18)F-FDG-PET/CT: A single-center prospective study.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.262866. doi: 10.2967/jnumed.121.262866.
    PubMed     Abstract available


  26. PROMTEANGTRONG C, Siripongsatian D, Jantarato A, Kunawudhi A, et al
    Head-to-head comparison of (68)Ga-FAPI-46 and (18)F-FDG PET/CT for evaluation of head and neck squamous cell carcinoma: a single-center exploratory study.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.262831. doi: 10.2967/jnumed.121.262831.
    PubMed     Abstract available


    September 2021
  27. GU B, Xu X, Zhang J, Ou X, et al
    The Added Value of (68)Ga-FAPI-04 PET/CT in Patients with Head and Neck Cancer of Unknown Primary with (18)F-FDG Negative Findings.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.262790. doi: 10.2967/jnumed.121.262790.
    PubMed     Abstract available


  28. VONK J, de Wit JG, Voskuil FJ, Tang YH, et al
    Epidermal growth factor receptor targeted fluorescence molecular imaging for postoperative lymph node assessment in patients with oral cancer.
    J Nucl Med. 2021 Sep 16. pii: jnumed.121.262530. doi: 10.2967/jnumed.121.262530.
    PubMed     Abstract available


    August 2021
  29. AVRAM AM, Zukotynski K, Nadel HR, Giovanella LM, et al
    MANAGEMENT OF DIFFERENTIATED THYROID CANCER: THE STANDARD OF CARE.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262402. doi: 10.2967/jnumed.121.262402.
    PubMed     Abstract available


    July 2021
  30. GIOVANELLA L, Avram A, Clerc J
    Molecular Imaging for Thyrotoxicosis and Thyroid Nodules.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  31. BERNET VJ, Chindris AM
    Update on the Evaluation of Thyroid Nodules.
    J Nucl Med. 2021;62.
    PubMed     Abstract available


  32. DE SOUZA FRANCA PD, Guru N, Kostolansky AR, Mauguen A, et al
    PARP1: A Potential Molecular Marker to Identify Cancer During Colposcopy Procedures.
    J Nucl Med. 2021;62:941-948.
    PubMed     Abstract available


    March 2021
  33. HOPE TA, Graces C, Calais J, Ehman E, et al
    Accuracy of (18)F-fluorocholine PET for the detection of parathyroid adenomas: prospective single center study.
    J Nucl Med. 2021 Mar 5. pii: jnumed.120.256735. doi: 10.2967/jnumed.120.256735.
    PubMed     Abstract available


    January 2021
  34. WHITMAN J, Allen IE, Bergsland EK, Suh IA, et al
    Assessment and comparison of fluorocholine PET and sestamibi scans in identifying parathyroid adenomas: a meta-analysis.
    J Nucl Med. 2021 Jan 15. pii: jnumed.120.257303. doi: 10.2967/jnumed.120.257303.
    PubMed     Abstract available


    May 2020
  35. CHENG L, Sa R, Luo Q, Fu H, et al
    Unexplained Hyperthyroglobulinemia in Differentiated Thyroid Cancer Patients Indicates Radioiodine Adjuvant Therapy: A Prospective Multicenter Study.
    J Nucl Med. 2020 May 1. pii: jnumed.120.243642. doi: 10.2967/jnumed.120.243642.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.